Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 31

PubMed

Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary? – PubMed -

Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?

  • 123456 Profile photo of Madelyn
    Catherine Marshall

    The editorial on the MAGNITUDE study – combination PARP inhibitor + abiraterone. Is biomarker testing necessary? They say yes.

Read the full article here
See more from Catherine Marshall